Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology
Market Cap
$6.61 Million
AU$10.68 Million AUD
Market Cap Rank
#33812 Global
#1196 in Australia
Share Price
AU$0.04
Change (1 day)
-16.67%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.34
About

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more

Bio-Gene Technology Ltd - Asset Resilience Ratio

Latest as of December 2025: 20.35%

Bio-Gene Technology Ltd (BGT) has an Asset Resilience Ratio of 20.35% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$300.00K
Cash + Short-term Investments
Total Assets
AU$1.47 Million
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Bio-Gene Technology Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Bio-Gene Technology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$300.00K 20.35%
Total Liquid Assets AU$300.00K 20.35%

Asset Resilience Insights

  • Good Liquidity Position: Bio-Gene Technology Ltd maintains a healthy 20.35% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Bio-Gene Technology Ltd Industry Peers by Asset Resilience Ratio

Compare Bio-Gene Technology Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Bio-Gene Technology Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Bio-Gene Technology Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 23.26% AU$500.00K AU$2.15 Million -24.22pp
2024-06-30 47.47% AU$1.50 Million AU$3.16 Million +46.46pp
2022-06-30 1.02% AU$74.20K AU$7.30 Million -77.64pp
2021-06-30 78.65% AU$3.93 Million AU$5.00 Million -4.82pp
2018-06-30 83.48% AU$6.40 Million AU$7.67 Million +62.30pp
2017-06-30 21.17% AU$2.00 Million AU$9.45 Million --
pp = percentage points